Pursuant to Regulation 30 of SEBI LODR 2015, we would like to inform you that the Board of Directors in its meeting today i.e., November 07, 2025, has approved the unaudited financial results ....
BAYERCROP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bayer CropScience reported Q2 FY26 revenue from operations of ₹15,534 million, down about 10.6% from ₹17,382 million in Q2 FY25. For the half year, revenue grew modestly to ₹34,680 million from ₹33,696 million, up roughly 2.9% YoY. Profit after tax for the quarter rose to ₹1,527 million (vs ₹1,363 million, up ~12%), taking H1 FY26 PAT to ₹4,314 million from ₹3,905 million. EPS for the quarter stood at ₹33.98. The Board declared an interim dividend of ₹90 per share (total payout ~₹4,045 million) with record date November 14, 2025 and payment on December 3, 2025. Net cash used in operating activities for H1 FY26 was negative at ₹349 million, continuing the working-capital-heavy cash flow pattern of the business. Auditor Deloitte Haskins & Sells LLP issued an unqualified limited review report.
The sharp Q2 revenue drop is a near-term concern, but higher profit growth and a generous ₹90 interim dividend (vs prior ₹35–₹70 range suggests healthy cash generation outlook) should support shareholder returns and limit negative stock reaction.